CYTOKINETICS INCORPOR

Cytokinetics Reports Second Quarter 2022 Financial Results

04 أغسطس 2022 15:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials

04 أغسطس 2022 06:30:01 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 أغسطس 2022 15:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics to Announce Second Quarter Results on August 4, 2022

21 يوليو 2022 15:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

05 يوليو 2022 15:00:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Pricing of $450 Million Convertible Senior Notes Offering

01 يوليو 2022 02:35:20 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Proposed Convertible Senior Notes Offering

29 يونيو 2022 15:35:18 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Date for FDA Advisory Committee Meeting to Review New Drug Application for Omecamtiv Mecarbil

24 يونيو 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil

17 يونيو 2022 06:30:00 بحسب Nasdaq GlobeNewswire

Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing COURAGE-ALS

16 يونيو 2022 06:30:00 بحسب Nasdaq GlobeNewswire